List of Excipients in Branded Drug FLEXBUMIN

FLEXBUMIN Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

FLEXBUMIN is a sterile, plasma-derived human albumin product supplied as 5% and 25% intravenous solutions. Its excipient strategy is built around two stabilizers, sodium caprylate and sodium acetyltryptophanate, with sodium chloride and water used to control tonicity and product presentation. The strongest commercial opportunities are in qualified excipient supply, plasma-protein stabilization, low-shear sterile manufacturing, container-closure systems, and albumin-compatible formulation technologies.

FLEXBUMIN is marketed by Takeda through its plasma-derived therapies portfolio. The product is regulated as a biologic, not as a conventional small-molecule drug. Its commercial protection therefore depends more on biologic manufacturing know-how, plasma supply, process validation, regulatory approvals, and contractual controls than on a conventional Orange Book patent estate.

What excipients are used in FLEXBUMIN?

FLEXBUMIN contains human albumin as the active protein and a defined set of stabilizing and tonicity-adjusting excipients.

Component	Functional role	Commercial relevance
Human albumin	Therapeutic protein and volume-expanding agent	Requires plasma sourcing, viral clearance, fractionation and release testing
Sodium caprylate	Protein stabilizer and anti-denaturation agent	Critical excipient for protein integrity during processing and storage
Sodium acetyltryptophanate	Protein stabilizer and antioxidant-supporting excipient	Used in plasma-protein formulations to reduce aggregation and oxidation risk
Sodium chloride	Tonicity and ionic-strength adjustment	Supports intravenous compatibility and product consistency
Water for injection	Sterile vehicle	Must meet parenteral water and endotoxin specifications

The FDA labeling for FLEXBUMIN identifies sodium caprylate and sodium acetyltryptophanate as stabilizers. The formulation also contains sodium chloride and water for injection. The label describes the product as a sterile, nonpyrogenic solution of human albumin prepared from human plasma by cold ethanol fractionation and additional manufacturing controls.[1]

The exact concentration of individual excipients can differ between the 5% and 25% presentations. Commercial decisions should therefore be made against the formulation and concentration-specific regulatory filing rather than against albumin products as a single category.

How do sodium caprylate and sodium acetyltryptophanate protect albumin?

Sodium caprylate and sodium acetyltryptophanate are established stabilizers for plasma-derived albumin. Their value comes from maintaining the protein’s conformational stability during fractionation, sterile filtration, filling, shipping and storage.

Sodium caprylate is a medium-chain fatty-acid salt. It interacts with hydrophobic regions of albumin and helps reduce structural disruption caused by temperature, interfaces and processing stress. It also has a long history of use in human albumin products.

Sodium acetyltryptophanate is an aromatic amino-acid derivative used to support albumin stability. It can help limit oxidative and conformational degradation under manufacturing and storage conditions.

The excipient system must be evaluated as a combination. Substituting one stabilizer without requalifying the other can change:

• Aggregation and particle formation
• Oxidation and degradation-product profiles
• Protein recovery after filtration
• Compatibility with tubing, bags and transfer assemblies
• Freeze-thaw and shipping stability
• Container-closure extractables and leachables
• Infusion-site tolerability
• Viral-clearance process performance

This limits the near-term opportunity for simple excipient substitution. The more defensible commercial opportunity is a qualified, supply-secure platform that preserves the existing stability profile while improving manufacturing economics or supply resilience.

What formulation differences exist between FLEXBUMIN 5% and 25%?

FLEXBUMIN 5% and 25% use the same therapeutic protein but serve different clinical and operational needs.

Attribute	FLEXBUMIN 5%	FLEXBUMIN 25%
Albumin concentration	5 g/100 mL	25 g/100 mL
Protein load per 100 mL	5 g	25 g
Primary use profile	Volume replacement and plasma-volume support	Hyperoncotic albumin replacement and fluid-mobilization applications
Formulation challenge	Larger infusion volume and container logistics	Higher protein concentration, viscosity and aggregation control
Excipient risk	Tonicity, infusion volume and container compatibility	Protein-protein interactions, viscosity, particulates and concentrated-product stability
Packaging economics	Higher volume per gram of albumin	Lower volume per gram but greater concentration-control requirements

The 25% presentation is more attractive for excipient and packaging innovation because it places greater stress on protein stability, viscosity, surface adsorption and particulate control. The 5% presentation creates a larger opportunity for efficient high-volume filling, bag design and logistics optimization.

Potential technical programs include:

1. Lower-shear filling and transfer systems for concentrated albumin.
2. Surface treatments that reduce protein adsorption to polymeric bags and tubing.
3. Improved bag films that reduce extractables and leachables.
4. Process analytical technology for turbidity, subvisible particles and protein aggregation.
5. Stability-indicating assays that detect oxidation and conformational change earlier.
6. Packaging systems that reduce oxygen and moisture transmission without increasing leachables.

What excipient suppliers can sell into the FLEXBUMIN supply chain?

The addressable market extends beyond the named excipients. Suppliers can compete across four layers.

Qualified stabilizer supply

Sodium caprylate and sodium acetyltryptophanate are the most direct opportunities. A supplier must demonstrate:

• Parenteral-grade purity
• Low bioburden and endotoxin control
• Consistent impurity profile
• Control of residual solvents and heavy metals
• Lot-to-lot compositional consistency
• Long-term supply capacity
• Change-control discipline
• Documentation suitable for a biologics manufacturing file

Because FLEXBUMIN is a licensed biologic, an excipient change is not equivalent to a routine formulation optimization. The supplier must support comparability, process validation and regulatory change management.

Custom excipient blends

A prequalified blend containing sodium caprylate, sodium acetyltryptophanate and sodium chloride could reduce dispensing errors and batch-preparation time. The opportunity is commercially attractive only if the blend improves manufacturing reliability without creating a new regulatory burden.

A blend supplier would need to control:

• Hygroscopicity
• Blend homogeneity
• Dissolution time
• Residual moisture
• Microbial limits
• Packaging compatibility
• Stability under warehouse conditions

Protein-compatible processing aids

Albumin is sensitive to interfaces and shear. Suppliers of single-use assemblies, low-binding filters, tubing, connectors and filling components can create value even when the formulation remains unchanged.

The best targets are components with:

• Low protein adsorption
• Low particulate shedding
• Low extractables and leachables
• Stable performance during high-protein concentration filling
• Validated sterilization compatibility
• Consistent performance across 5% and 25% products

Container-closure systems

FLEXBUMIN is supplied in flexible containers. Container materials and overwrap systems affect oxygen exposure, light protection, leakage, shipping durability and administration efficiency.

Commercial opportunities include:

• Low-oxygen-permeability multilayer films
• Improved port and connector designs
• Tamper-evident overwraps
• Reduced-volume secondary packaging
• Recyclable or lower-material packaging
• Integrated administration systems
• Cold-chain monitoring and package integrity indicators

Packaging changes may be commercially easier to implement than a new stabilizer because they can improve product quality and logistics without changing the active formulation. They still require extractables, leachables, sterility, container-closure integrity and stability data.

How strong is the FLEXBUMIN formulation patent estate?

FLEXBUMIN’s principal competitive barriers are unlikely to resemble the patent estate for a small-molecule product.

Protection category	Relevance to FLEXBUMIN	Commercial assessment
Orange Book patents	Limited	FLEXBUMIN is a biologic product rather than a conventional NDA drug
Composition-of-matter patents	Limited for naturally occurring human albumin	Albumin itself is not a typical new chemical entity
Stabilizer formulation patents	Possible	Narrow claims may cover concentrations, ratios, pH or processing conditions
Manufacturing patents	High potential value	Fractionation, viral clearance, purification and filling controls can be difficult to replicate
Trade secrets	High	Plasma pooling, process parameters, analytical methods and release criteria may not be publicly reproducible
Regulatory exclusivity	Relevant historically	Biologic reference-product and application exclusivity depend on the applicable FDA pathway and approval history
Plasma supply controls	High	Access to qualified plasma and fractionation capacity can limit competition

No conventional Orange Book-based patent expiry date should be used as the primary forecast for FLEXBUMIN generic entry. A product-level analysis should instead review FDA biologic records, Purple Book status, published patent claims, regulatory exclusivity, manufacturing disclosures and litigation databases.[2,3]

A narrow formulation patent covering sodium caprylate, sodium acetyltryptophanate or a specific albumin concentration would not necessarily prevent all competing albumin products. A competitor could attempt a different stabilizer system, concentration, container or manufacturing process. The practical strength of such claims depends on whether they cover the commercial product broadly enough to capture design-around formulations.

When does FLEXBUMIN lose exclusivity?

FLEXBUMIN does not have a single small-molecule-style loss-of-exclusivity date that can be inferred from an Orange Book listing.

The relevant commercial milestones are:

Milestone	Significance
FDA biologic approval	Establishes the reference product and approved manufacturing process
Biologic exclusivity period	Limits certain biosimilar applications or approvals for the statutory period
Patent expiry	May restrict specific formulations, processes or uses
Manufacturing comparability	Determines whether a competitor can reproduce quality attributes
Plasma supply qualification	Affects the speed and scale of competitive entry
State substitution and payer policy	Determines practical uptake after approval

FLEXBUMIN has been marketed for many years, so any original statutory exclusivity period is unlikely to be the main current barrier. The commercial defense is more likely to rest on manufacturing complexity, quality consistency, procurement relationships and the difficulty of establishing a large-scale plasma-derived albumin operation.

Are biosimilar or generic challenges possible for FLEXBUMIN?

A biosimilar pathway is legally possible for biologic products, but plasma-derived albumin creates technical and commercial challenges.

Biosimilar development barriers

A competing applicant would need to demonstrate similarity across a complex set of attributes, including:

• Albumin identity and amino-acid sequence
• Higher-order structure
• Binding activity
• Fatty-acid and ligand association
• Oxidation and glycation profiles
• Aggregation and particle levels
• Purity and related proteins
• Viral safety
• Sterility and endotoxin control
• Pharmacokinetic behavior
• Clinical or comparative evidence appropriate to the proposed indication

Albumin is derived from human plasma rather than produced by recombinant cell culture. The manufacturing process includes plasma sourcing, pooling, fractionation, purification and viral-reduction steps. A biosimilar applicant therefore faces both product-comparability and supply-chain requirements.

Generic substitution risk

Automatic pharmacy substitution is less straightforward than with many oral generics. Hospital formularies, group purchasing organizations, state substitution rules, payer contracts and clinician familiarity may determine uptake.

The most plausible competitive scenarios are:

1. An additional plasma-derived albumin product with a different trade name.
2. A biosimilar or interchangeable biologic designation, if supported by the regulatory record.
3. A regionally manufactured albumin product competing on price or supply.
4. A recombinant or engineered albumin substitute for selected applications.
5. A formulation differentiated by concentration, container or administration system.

Which companies compete with FLEXBUMIN?

The competitive set includes manufacturers of human albumin and other plasma-derived therapies. Key participants have included CSL Behring, Grifols, Kedrion, Octapharma and other regional plasma fractionators. Competitive intensity varies by geography and by access to plasma collection, fractionation capacity and hospital procurement channels.

Competitor type	Example strategic advantage	Main limitation
Large plasma fractionators	Plasma network, manufacturing scale and hospital access	High fixed costs and regulatory complexity
Regional albumin manufacturers	Local supply and procurement advantages	Smaller production scale
Recombinant albumin developers	No human plasma input and potentially more controllable supply	Clinical adoption and cost hurdles
Formulation innovators	Differentiated concentration, packaging or administration	Limited ability to change established clinical practice
Excipient and packaging suppliers	Lower capital requirement and cross-product leverage	Long qualification cycles and customer concentration

For an excipient supplier, competing directly with an albumin manufacturer is usually less attractive than selling into several albumin, immunoglobulin and coagulation-factor programs. The same protein-stabilization and low-binding technologies can support multiple plasma-derived products.

What licensing deals and partnerships matter?

Publicly disclosed FLEXBUMIN-specific excipient licensing arrangements are not a reliable basis for valuation. The relevant partnership structures are more likely to involve:

• Plasma collection and fractionation agreements
• Contract manufacturing
• Single-use manufacturing systems
• Container and bag supply
• Excipient qualification agreements
• Hospital purchasing contracts
• Regional distribution rights
• Technology licenses for recombinant albumin or albumin substitutes

An excipient company should favor a supply agreement with technical-transfer and change-control provisions over a narrow royalty license unless the excipient has composition-of-matter or process claims that materially constrain alternatives.

Important contract provisions include:

• Minimum annual purchase volumes
• Dual-source qualification rights
• Price-adjustment formulas
• Raw-material traceability
• Audit and inspection rights
• Regulatory-support obligations
• Deviation and recall allocation
• Change-notification periods
• Business-continuity requirements
• Geographic exclusivity

What litigation affects FLEXBUMIN and albumin products?

There is no widely recognized Orange Book Paragraph IV litigation model that defines FLEXBUMIN competition. The main legal risks are more likely to arise from:

• Patent disputes over albumin formulations or manufacturing methods
• Trade-secret claims involving fractionation and purification
• Contract disputes over plasma or excipient supply
• Product-liability claims
• Manufacturing deviations and recalls
• Regulatory disputes over biosimilarity or interchangeability
• Procurement disputes involving hospital systems and government buyers

Paragraph IV litigation is generally associated with ANDA products and listed small-molecule drugs. A FLEXBUMIN competitor using a biologic pathway would more likely face patent-certification, BPCIA notice and patent-exchange issues rather than a conventional Paragraph IV case.[2]

What FDA regulatory requirements apply to FLEXBUMIN excipients?

Excipient changes in a sterile biologic require a risk-based comparability package. Depending on the change, the regulatory submission may require:

• Updated raw-material specifications
• Supplier qualification
• Batch analysis
• Stability studies
• Protein aggregation and particle testing
• Sterility and endotoxin data
• Process validation
• Container-closure compatibility
• Extractables and leachables studies
• Viral-safety impact assessment
• Manufacturing comparability
• Updated Chemistry, Manufacturing and Controls information

The lowest-risk commercial strategy is to maintain the existing excipient identities and improve supply, purity, packaging or manufacturing consistency. A new stabilizer system offers greater differentiation but creates a higher regulatory burden and may require clinical bridging.

What revenue exposure does FLEXBUMIN create for suppliers?

Takeda does not generally report FLEXBUMIN revenue as a separately disclosed public line item. Product-level revenue exposure must therefore be estimated from hospital demand, albumin utilization, regional pricing and procurement share rather than from audited product sales.

Revenue drivers include:

• Albumin use in critical care and surgery
• Liver disease and cirrhosis treatment protocols
• Plasma exchange
• Volume resuscitation practices
• Hospital tender awards
• National plasma supply
• Reimbursement policy
• Shortage conditions
• Concentration mix between 5% and 25%

For an excipient supplier, the direct revenue opportunity is smaller than the albumin drug market but can be more scalable if the same qualified excipient platform is sold to several plasma-derived products. The principal value is recurring supply revenue protected by long qualification cycles and high switching costs.

What is the best commercial strategy for FLEXBUMIN excipients?

The strongest strategy is a staged program.

Phase 1: Supply assurance

Offer pharmacopeial-grade sodium caprylate and sodium acetyltryptophanate with redundant manufacturing, validated impurity controls and long-term capacity commitments.

Phase 2: Process integration

Bundle excipients with formulation-preparation services, dispensing controls and manufacturing documentation. The goal is to reduce batch variability and operator handling.

Phase 3: Packaging and compatibility

Develop low-binding bags, tubing and connectors validated for 5% and 25% albumin. This creates a broader product platform than selling a single commodity excipient.

Phase 4: Next-generation formulation

Pursue new stabilizer systems, recombinant albumin compatibility or concentrated presentations only after establishing a strong regulatory and analytical foundation.

The near-term opportunity is defensive and operational: protect supply, reduce variability and improve container performance. The longer-term opportunity is a differentiated albumin platform with lower manufacturing loss, improved stability and more efficient administration.

Key Takeaways

• FLEXBUMIN uses human albumin with sodium caprylate, sodium acetyltryptophanate, sodium chloride and water for injection.
• Sodium caprylate and sodium acetyltryptophanate are the core stabilizers and the most direct excipient targets.
• The 25% presentation creates greater technical opportunity in aggregation, viscosity, particle control and low-binding packaging.
• FLEXBUMIN is a biologic, so Orange Book analysis and conventional Paragraph IV forecasting are limited.
• Manufacturing know-how, plasma supply, quality systems and regulatory comparability are more important barriers than a conventional composition-of-matter patent.
• The best supplier opportunity is a qualified platform covering stabilizers, single-use components, container systems and analytical controls.
• Product-level FLEXBUMIN revenue is not separately disclosed by Takeda, so commercial exposure should be modeled through albumin utilization, procurement and regional pricing.
• A new excipient system offers differentiation but carries materially higher regulatory and comparability risk than improving the existing excipient supply chain.

FAQs About FLEXBUMIN Excipient and Commercial Strategy

Is sodium caprylate in all FLEXBUMIN presentations?

FLEXBUMIN labeling identifies sodium caprylate as a stabilizer. The concentration and total excipient load should be assessed separately for the 5% and 25% presentations.

Can a competitor use a different stabilizer instead of sodium acetyltryptophanate?

Potentially, but a different stabilizer system would require extensive comparability, stability, safety and regulatory support. It would not automatically avoid all formulation or process patents.

Does FLEXBUMIN have an Orange Book patent expiration date?

FLEXBUMIN is a biologic product, so an Orange Book patent-expiration date should not be treated as the primary exclusivity metric. Biologic records, patent claims and regulatory exclusivity are more relevant.

Are albumin products interchangeable with FLEXBUMIN?

Interchangeability depends on the competitor’s FDA approval pathway and designation. Similar albumin concentration alone does not establish biosimilarity or interchangeability.

Which FLEXBUMIN presentation offers the greatest packaging opportunity?

FLEXBUMIN 25% generally offers greater technical differentiation because concentrated albumin places higher demands on viscosity management, protein adsorption, particulate control and container compatibility.

References

1. U.S. Food and Drug Administration. (2023). FLEXBUMIN 5% and FLEXBUMIN 25% prescribing information. Takeda Pharmaceuticals U.S.A., Inc.

2. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biologic product information. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

4. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

5. European Medicines Agency. (2024). Guideline on similar biological medicinal products. https://www.ema.europa.eu/ en/human-regulatory-overview/biosimilar-medicines-overview.